Federal Register
Notice: FDA is providing notice of a memorandum of understanding between FDA and Duke University, on behalf of its Duke Clinical Research Institute (DCRI). FDA and Duke agree to collaborate in a "Cardiac Safety Research Consortium" through steering committees and technical working groups, to develop strategic plans, set priorities, and leverage resources and expertise from multiple sources, including the private sector, toward the goals of identifying indicators of cardiovascular risk, predicting adverse cardiovascular events associated with therapeutic interventions, improving the clinical utility of biomarker technologies as diagnostic and assessment tools that facilitate the development of safer and more effective cardiovascular therapies, diagnostic, and assessment tools. To view this notice, click here.